Oppenheimer believes in DexCom amid government push for wearables, particularly glucose monitors.

From Yahoo Finance: 2025-06-29 12:53:00

Oppenheimer reaffirmed its $95 price target and Outperform rating for DexCom, Inc. (NASDAQ:DXCM) in response to Health and Human Services Secretary RFK Jr.’s remarks about a significant wearables campaign. Secretary Kennedy declared that HHS would launch a major advertising campaign to promote wearables, especially glucose monitors. This news is encouraging for companies like DexCom that provide continuous glucose monitoring (CGM) systems. DexCom is currently leading a randomized controlled trial for Medicare patients with non-insulin Type 2 diabetes. While DXCM shows investment potential, some AI stocks may offer greater upside. No promotional content included.



Read more at Yahoo Finance: Oppenheimer Reaffirms DexCom Buy Rating Amid HHS Wearables Push